Stockscreener 앱 받기
3.53
1.94%
-0.08
Soligenix Inc 주식(SNGX)의 최신 뉴스
Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024 - PR Newswire
Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024 - StockTitan
European patent granted to Soligenix for synthetic hypericin production - Investing.com India
European patent granted to Soligenix for synthetic hypericin production By Investing.com - Investing.com Canada
European patent granted to Soligenix for synthetic hypericin production - Investing.com
Soligenix Receives European Patent for Improved Production of Synthetic Hypericin - Quantisnow
T-Cell Lymphoma Pipeline Assessment 2024 | Clinical Trials, Latest Approvals, Treatment Outlook, Competitive Landscape, Key Companies | Soligenix, CStone Pharmaceuticals, Genor Biopharma, Innate Pharm - Barchart
Soligenix Announces Recent Accomplishments And Second Quarter 20 - GuruFocus.com
Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Ph - GuruFocus.com
Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire
Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - StockTitan
Soligenix to Present at The Microcap Conference - GuruFocus.com
SNGX: Phase 3 Trial of HyBryte™ in CTCL to Initiate in 2H24… - Zacks Small Cap Research
SNGX: Phase 3 Trial of HyBryte™ in CTCL to Initiate in 2H24… - Yahoo Finance
Soligenix Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Soligenix Trumpets Q2 Numbers - MSN
Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results - citybiz
Soligenix Trumpets Q2 Numbers - Baystreet.ca
Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results - PR Newswire
Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results - StockTitan
Cutaneous T-cell Lymphoma Market Forecasted to Surge in Coming - openPR
Strong Clinical Momentum for Soligenix's HyBryte™ in Treating Cutaneous T-Cell Lymphoma; PCG Digital Exclusive with Dr. Brian Poligone - BioSpace
Strong Clinical Momentum for Soligenix's HyBryte™ in - GlobeNewswire
Strong Clinical Momentum for Soligenix's HyBryte™ in Treating Cutaneous T-Cell Lymphoma; PCG Digital Exclusive with Dr. Brian Poligone - Yahoo Finance
Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results - Kilgore News Herald
Soligenix (NASDAQ:SNGX) & Marker Therapeutics (NASDAQ:MRKR) Head-To-Head Contrast - Defense World
Soligenix regains compliance with Nasdaq listing standards - Investing.com
Soligenix regains compliance with Nasdaq listing standards By Investing.com - Investing.com Canada
Soligenix regains compliance with Nasdaq listing standards - Investing.com India
Check Out Soligenix Inc (SNGX)’s Trade Data Rather Than the Analysts’ Views - SETE News
Soligenix Inc (SNGX) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
Cutaneous T-Cell Lymphoma Drugs Market Size 2034 | BeiGene, - openPR
PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's Hy - WICZ
PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix’s HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results - ForexTV.com
PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial - U.S. Politics Today
PRISM MarketView Features Q&A with Dr. Ellen Kim: - GlobeNewswire
PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results - Yahoo Finance
What was Soligenix Inc (SNGX)’s performance in the last session? - US Post News
Trading Day Review: Soligenix Inc (SNGX) Loses Momentum, Closing at 7.65 - The Dwinnex
Soligenix Updates on Heat-Stable Vaccines and Oncology Advances - Proactive Investors USA
Soligenix Updates on Heat-Stable Vaccines and Oncology Advances - Proactive financial news
Soligenix Updates on Heat-Stable Vaccines and Oncology Advances - Proactive Investors Australia
Soligenix Updates on Heat-Stable Vaccines and Oncology Advances - Proactive Investors UK
Soligenix Inc (SNGX): An Important Analyst Insights - Stocks Register
Crude Oil Down 1%; Soligenix Shares Surge - MSN
Uncover Why This Pharma Stock Jumped 400% on Study Update - MSN
SNGX: Positive Interim Results for HyBryte in Investigator-Initiated Study in CTCL Raising Valuation to 35 - Research Tree
Soligenix (NASDAQ: SNGX) Stock Skyrockets on $4.2 Million Funding Boost - ABBO News
Uncover Why This Pharma Stock Jumped 400% on Study Update - sharewise
SNGX: Positive Interim Results for HyBryte™ in Investigator-Initiated Study in CTCL; Raising Valuation to $35… - Yahoo Finance
Uncover Why This Pharma Stock Jumped 400% on Study Update - MarketBeat
5 Investors Betting Big on Soligenix (SNGX) Stock - InvestorPlace
Ebola Virus Infection Market to Witness Huge Growth - openPR
Soligenix secures funding through warrant agreement - Investing.com India
Soligenix secures funding through warrant agreement By Investing.com - Investing.com India
Soligenix secures funding through warrant agreement - Investing.com
S&P 500 Edges Higher; Indivior Shares Plummet - Benzinga
Soligenix Shares Soar on Positive Data for Extended HyBryte as Cancer Treatment - MarketWatch
Soligenix secures funding through warrant agreement By Investing.com - Investing.com UK
Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Benzinga
Soligenix stock rallies 400% on positive HyBryte trial results - Invezz
Crude Oil Down 1%; Soligenix Shares Surge - Benzinga
Stocks Mixed Following Powell Testimony - Schaeffers Research
Soligenix (Nasdaq: SNGX) Shines a Light on Rare Diseases - All Finance Times
1.19%
1.65%
자본화:
|
볼륨(24시간):